^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IRX4204

i
Other names: VTP194204, rexinoid, IRX4204, NRX194204, AGN-194204, ALRT-4204, NRX-4204, VTP-194204, IRX-4204, IRX 4204, NRX4204, NRX 4204, NRX 194204, NRX-194204, AGN194204, AGN 194204, VTP 194204
Company:
Io Therap
Drug class:
Retinoid X receptor agonist
8ms
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC (clinicaltrials.gov)
P1, N=12, Suspended, Io Therapeutics | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
erlotinib • IRX4204
1year
The RXR agonist, IRX4204, delays the formation of Brca1 mutant mammary tumors via modulation of the anti-tumor immune response (SABCS 2023)
These data demonstrate a novel use of the RXR agonist, IRX4204, to delay the formation of Brca1-deficient mammary tumors. We have found that IRX4204 treatment modulates the tumor immune response through increased infiltration of cytotoxic CD8-positive T-cells in Brca1-deficient mammary tumors in vivo. We have also determined that IRX4204 modulates lipid metabolism in breast cancer cell lines in vitro.
BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • CD8 (cluster of differentiation 8) • CASP3 (Caspase 3)
|
BRCA1 mutation • CD8 positive • BRCA1 expression
|
IRX4204
over1year
RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. (PubMed, Cells)
We investigated the effects of RXR agonists (LG100754, bexarotene, AGN194204, and LG101506) on lenalidomide's anti-myeloma activity, T cell functions, and the level of glucose and lipids in vivo. LG100754 retained its glucose- and lipid-lowering effects. RXR agonists demonstrate potential utility in enhancing drug sensitivity and T-cell function in the treatment of myeloma.
Journal
|
CRBN (Cereblon)
|
CRBN expression
|
lenalidomide • IRX4204 • Targretin oral (bexarotene oral)
4years
Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses. (PubMed, Blood)
Notably, IRX4204 reduced in vitro human T cell proliferation and enhanced Treg generation in mixed lymphocyte reaction cultures. Collectively, these beneficial effects indicate that targeting RXRs with IRX4204 could be used as a novel approach to prevent acute GVHD in the clinic.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FOXP3 (Forkhead Box P3)
|
FOXP3 expression
|
IRX4204